Which PET tracer shows prostate cancer recurrence better?

NCT ID NCT06604442

Completed Diagnosis Sponsor: Blue Earth Diagnostics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study compared two radioactive tracers, piflufolastat (18F) and flotufolastat (18F), used in PET scans to detect prostate cancer that has returned after surgery. The main goal was to see which tracer produces less radioactivity in the bladder, which can interfere with image clarity. The study involved 62 men with low PSA levels (≤0.5 ng/mL) and a history of prostate cancer recurrence after radical prostatectomy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: piflufolastat (18F) and flotufolastat (18F) (radioactive tracers for PET scans)
What this could lead to: If successful, this could help doctors choose the PET tracer that gives clearer images of recurrent prostate cancer, potentially improving detection.
What could go wrong: This is a small, completed Phase 4 study focused on comparing bladder radioactivity, not on patient outcomes. The results may not change clinical practice or directly improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Endeavor Health- Glenbrook Hospital

Glenview, Illinois, 60026, United States
Mayo Clinic

Phoenix, Arizona, 85054, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Montefiore Medical Center

The Bronx, New York, 10461, United States
Tower Urology

Los Angeles, California, 90048, United States
Urology San Antonio

San Antonio, Texas, 78229, United States
XCancer Omaha/Urology Cancer Center

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.